VITRAC Therapeutics Initiates a Phase I/II Clinical Trial with the Aurora Kinase A inhibitor VIC-1911 in GVHD Prophylaxis

VITRAC Therapeutics, LLC initiated a Phase I/II clinical trial of VIC-1911 in combination with sirolimus and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in myeloablative allogeneic stem cell transplantation. V